Description:
Melanoma is the most serious type of skin cancer and develops in the cells that produce melanin. Treatment for early-stage melanomas usually include surgery to remove the melanoma. If the melanoma has spread beyond the skin, treatment options may include surgery to remove affected lymph nodes and chemotherapy.
An effective new drug delivery system has been discovered for oral and topical administration of a promising anti-cancer agent for the treatment of melanoma. A self-emulsifying nanoemulsion system was developed for oral delivery that has resulted in entrapment efficiency of 90% with 90% of the drug released within two hours in simulated gastric fluid. The formulation had similar efficacy applied topically when solubilized in DMSO with no side effects in mice. The compound can also be applied topically as a transdermal, nano-emulsion cream as a preventative treatment or as a post-surgical treatment to prevent relapse of melanoma.
Reference Number: D-1052
Market Applications:
• Cancer therapeutics
• Natural supplements
Features, Benefits & Advantages:
• Safer drug-delivery system
• Non-toxic
• Stable up to six months
• High entrapment efficiency and subsequent release
• In-vivo delivery
• Topical or oral application
Intellectual Property:
A U.S. Provisional Patent, Serial 62/189,377 was filed on 07/07/2015. Patent was not pursued and has expired (HJ 4/17/18)
Development Stage:
This invention has been reduced to practice in vitro, ex vivo and in vivo.
Researcher:
Sanjay Srivastava, PhD, Biomedical Sciences, Texas Tech University Health Sciences Center, School of Pharmacy, Amarillo, Texas.
Keywords: melanoma, oral, topical, nanoemulsions